Please login to the form below

Not currently logged in
Email:
Password:

Pharma deals during June 2014

Deal Watch: Major pharma collaborations, acquisitions and agreements in the past month

Deal watchWelcome to Deal Watch for June 2014, our monthly analysis of the top pharma deals. In line with customary practice, this review focuses predominantly on those deals where financial terms are disclosed during June.  So, as we move into the summer of 2014, what's hot and happening in terms of deals this month?

Deal values hotting up…
Acquisitions lead the way and topping the table at $42.9bn was the acquisition of Covidien (based in Dublin) by Medtronic. Already a major contender in medical devices, this deal – the largest in the medical device field – means the combined company is a serious competitor to the market leader, J&J. An interesting aspect of the deal is the base of the company being in Ireland, offering a clear tax benefit. This was a key feature in the previous month's bid by Pfizer to acquire AstraZeneca (AZ) to take advantage of the lower tax rate in the UK compared to that in the US 

It was a busy month for Medtronic as the company also announced the signature of a memorandum of understanding with Sanofi to enter into a global strategic alliance in diabetes. It is intended to base the alliance on an open innovation model with Sanofi bringing its extensive insulin portfolio and Medtronic contributing its insulin pumps and glucose monitoring expertise. No financial terms have been disclosed. 

Next in the top headlines was the $3.9bn acquisition of Idenix by Merck & Co representing $24.50 per share in cash and a 239 per cent premium over the share price on the Friday before the announcement. The juggernaut that is the hepatitis C deal machine rolls on with this deal keeping the cost-of-entry price tag up. The Merck & Co acquisition brings three oral hepatitis C compounds which are in clinical development and offers the promise of a triple therapy which could prove effective in all genotypes. Merck has its own products in development and this deal marks a long term investment and determination in this field. The table below shows the rather expensive range of deals closed in this intensely competitive field over the last few years. The acquisitions are not without risk as BMS found when, seven months after paying $2.5bn, it had to discontinue development of Inhibitex product INX-189 in phase II because of safety issues.  

Major hepatitis C deals

Licensor acquired / licensee acquirer

Product

Status at Deal/ Date

Deal type

Headline ($m)

Idenix/
Merck & Co
Samtasvir (NS5A inhibitor) + other HCV therapies
Phase II
June 2014
Acquisition (announced), 239% premium
 3,900
Pharmasset/ Gilead
Solvadi / PSI-7977
Phase III
Nov 2011
Acquisition, 89% premium
 10,800
Inhibitex/ BMS
INX-189 / BMS 986094
Phase II
Jan 2012
Acquisition, 163% premium
2,500
Alios BioPharma/ Vertex
ALS-2200/ALS-2158 (HCV polymerase inhibitors)
Preclinical
June 2012
Global licence   
1,525 (60 upfront)
Enanta/ Novartis
EDP-239 (NS5A inhibitor)
Preclinical
Feb 2012 
Exclusive global licence, US co-promotion
440

Key to any deal price tag of course is the product valuation. Idenix' negotiation position will have been helped no end by the price and recent US sales of Gilead's Sovaldi (sofosbuvir); the US price is $84,000 (for a 12 week course) with sales of $2.27bn in the first quarter of this year. It was inevitable that such a high price would attract attention from the regulators; although the UK price is lower than that in the US (the UK list price is £35,983 for a 12 week course), NICE is now questioning Gilead's data, stating that evidence is lacking in some sub groups and indicating that there are uncertainties in the evidence base. So the jury is out until October 2014 when a decision is expected.

Although not commanding quite such a high headline, this month OraSure granted AbbVie exclusive promotion rights to its OraQuick HCV test in the US for $75m. This deal shows Sanofi is clearly not alone in taking a broad approach to franchise management!

A Midsummer Night's Dream
Now formally off the table and staying unrequited was the acquisition bid made by Pfizer for AZ, the failure of which was attributed by Pfizer's CFO on the sole issue of price. 

Clearly not deterred by this, AZ has moved on to build on its respiratory franchise by in-licensing Synairgen's inhaled beta interferon SNG001. This product is in development as an immuno-modulatory therapy for viral respiratory tract infections in patients with severe asthma. The deal carries a headline value of $232.25m which includes a $7.25m upfront fee. Seeing some success from its partnering, AZ also marked the start of a clinical trial with the antisense drug ISIS-ARRx, in patients with metastatic castrate-resistant prostate cancer, by paying its partner Isis Pharmaceuticals a $15m milestone.

Staying in the hostile M&A arena, Allergan declined Valeant's second takeover bid, so this story still rumbles on but Valeant is not yet giving up. The company announced that an exchange offer for Allergan's common stock would go ahead taking its May 30 proposal directly to the shareholders; so watch this space.

Hot gossip
Rumours were posted by the Financial Times that Shire was about to make a $5bn bid for NPS Pharmaceuticals. So strong were the rumours that this led to NPS issuing an official denial. Next up was the comment that Allergan was on the cusp of making a bid for Shire, but of course it was pipped at the post by AbbVie confirming that a $46bn bid ($78.89 per share) had been made (the 28 day offer period closes on July 18).  This offer has been rejected but any move on NPS cannot now go forward as the UK Takeover Code restricts companies from acquiring assets that could be deemed to deter the acquisition during the offer period.

So on a lower scale, Shire remains busy focusing on the day to day business with a move into specialised patient populations targeting the pre-school market via a new clinical study with Vyvanse. Success in this endeavour could secure a six-month data exclusivity. Also building on its R&D collaboration with arGEN-X, Shire entered into a long term alliance paying an upfront of $20.4m (cash and equity) for access to therapeutic antibodies in cancer and autoimmune diseases.

Streamlining is evident at Teva with the company undertaking a major cost cutting exercise.  But it is also looking to build on its pain franchise as noted with its purchase of Labrys Biologics for up to $825m. This brings access to Labrys' monoclonal antibody drug LBR-101, which is under development for the prevention of chronic and episodic migraine and will clearly complement Copaxone.

Oncology focus and immuno-oncology is still growing
Still keeping its place in the headlines and following its recent licence with Nogra Pharma with the notable $710m upfront payment, Celgene closed a deal with NanoString Technologies for the development of a companion diagnostic assay to support the development of Revlimid for treatment of Diffuse Large B-Cell Lymphoma at a more modest headline of $45m.

Of course the growth area within oncology is the immunological approach and GSK closed a $350m co-development and option deal with Adaptimmune. Adaptimmune develops TCR engineered T-cells and the agreement focuses on co-development around the cancer testis antigen NY-ESO-1, to which GSK has an option on the programme though to clinical proof of concept.

Similarly, Pfizer signed up with the French company Cellectis for its CAR-T platform which uses chimeric antigen receptors to reprogramme T-cells to target cancers.  Under the terms of the agreement, Pfizer secured exclusive development and marketing rights for 15 targets selected by Pfizer.

Cellectis has reserved 12 other targets and Pfizer will provide preclinical development assistance for four of these. Deal terms include an $80m upfront payment, R&D funding and up to $185m in milestones for each candidate, giving an estimated headline value of $2.8 bn.  In addition, Pfizer has agreed to make a 10 per cent equity investment stake purchasing new shares at €9.25 ($12.63) each, representing an estimated $28m. Instead of arriving at a personalised solution by harvesting individual patient's T-cells, Cellectis is using allogenic CAR-Ts to provide a treatment which should be manufactured and standardised more easily.  Cellectis plans to open a research site in the US to work more closely with Pfizer.

Joining the checkpoint modulator fray, Merck Serono formed a partnership with Morphosys to discover and develop antibodies against certain immune checkpoints using the Morphosys Ylanthia platform. Financial terms were not disclosed but include milestone and royalties.

Staying with the mid-caps and turning to prostate cancer, Bayer and Orion entered into a joint development deal for ODM-201. This phase III-ready, androgen receptor inhibitor therapy will supplement Bayer's oncology pipeline. The phase II results showed a decline in PSA levels of more than 50% in the study of 124 patients. Bayer paid €50m ($68m) upfront payment with further milestones in return for global rights which should complement Xofigo (from the acquisition of Algeta).  The companies will jointly fund the phase III trials.  Orion will retain co-promotion rights in Europe.

Facing the music 
Not all of the deals announced this month are related to innovations and acquisitions. Reflecting some of the news flow, we saw Pfizer make a settlement of $325m for the alleged improper marketing of Neurontin. Pfizer is not the only major pharma in this position; also this month GSK settled US claims of irregular marketing activities in asthma and antidepressants at a reported $105m.

So the deals keep flowing as we move into the summertime. It will be interesting to see how the major acquisitions play out, following the closure of the Pfizer-AZ saga. Could this be the summer of unrequited proposals?

See a table listing all the major pharma mergers, acquisitions and collaborations agreed during June 2014

Article by
Sharon Finch

Sharon is the founder and CEO of Medius Associates.

She has worked in business development since joining the industry bringing more than 30 years proven experience. With a comprehensive knowledge of business development and licensing, she has extensive experience of identifying, creating, implementing and directing international business deals. In the last 12 months, Sharon has closed on three major client deals.

9th July 2014

Article by
Sharon Finch

Sharon is the founder and CEO of Medius Associates.

She has worked in business development since joining the industry bringing more than 30 years proven experience. With a comprehensive knowledge of business development and licensing, she has extensive experience of identifying, creating, implementing and directing international business deals. In the last 12 months, Sharon has closed on three major client deals.

9th July 2014

From: Research, Sales

Share

Tags


Career advice

No results were found

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Infographics